AHR and cancer: Taken together, these preclinical results unveil complex signaling pathways between the Trp catabolic enzymes IDO1and TDO2, the Kyn and the ligand-operated transcription factor AhR, which is dysregulated by cancer cells to highjack antitumor immunity and develop resistance to anticancer therapies, particularly in the immunotherapy era.